| Accession |
PRJCA019805 |
| Title |
Pelcitoclax (APG-1252) combined with osimertinib in patients (pts) with EGFR-mutant non-small-cell lung cancer (NSCLC) |
| Relevance |
Medical |
| Data types |
Clinical trial data
|
| Organisms |
Homo sapiens
|
| Description |
Establish the recommended phase 2 dose (RP2D) Safety, efficacy, and pharmacokinetic (PK) profiles |
| Sample scope |
Multiisolate |
| Release date |
2023-10-25 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Ascentage(Suzhou)Pharma Group Inc
|
|
NA
|
|
|
|
| Submitter |
Li
Zhang (zhangli@sysucc.org.cn)
|
| Organization |
Sun Yat-sen University Cancer Center |
| Submission date |
2023-09-15 |
